Ontario, Canada (CU)_ According to Sun Pharmaceutical Industries’ statement on Thursday, its subsidiary has introduced a new therapy for dry eye condition known as Cequa in the Canadian market. Cequa (cyclosporine ophthalmic solution 0.09 percent w/v), a calcineurin inhibitor immunomodulator, has been launched by Sun Pharma Canada Inc, which is a wholly-owned subsidiary of the Mumbai-based pharma giant.
According to Sun Pharma’s statement, the medicine is the first dry eye treatment available in Canada that utilizes nanomicellar (NCELL) technology, which enhances the bioavailability and physicochemical stability of cyclosporine, thereby improving ocular tissue penetration.
Abhay Gandhi, CEO of Sun Pharma North America, expressed delight over the launch of the new medication for the dry eye condition. He said, “We are excited to introduce CEQUA as a new treatment option for the more than six million Canadians living with dry eye disease”. He noted that the introduction of this medicine marks a significant landmark for the pharmaceutical company as it continues to develop its ophthalmic portfolio in Canada.
W Bruce Jackson, MD, former Professor and Chair, Department of Ophthalmology, McGill University and the University of Ottawa, highlighted the benefits of the new medication. He said, “Cequa, with its nanomicellar technology and increased strength of cyclosporine, can be an important addition to our treatment options as eye care professionals strive for more personalized treatment”.
Gandhi stated that the product exhibits the company’s dedication to developing novel medications that support patient and physician choice. Dry eye illness occurs when the amount or the quality of tears are insufficient to adequately moisten the surface of the eye. An itchy sensation or the sensation that something is in the eye are symptoms of the condition.
